Copyright
©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Jul 10, 2011; 2(7): 281-288
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.281
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.281
Table 1 Randomized trials comparing Rituximab-chemotherapy vs chemotherapy alone in follicular lymphoma patients
Reference | Year | Prior treatment | Treatment | No of patients | ORR | OS | PFS |
Marcus et al[3,4] | 2005, 2008 | No | R-CVP vs CVP | 321 | 81% vs 57% (P < 0.001) | 83% vs 77% at 4-years (P = 0.029) | 27 vs 7 mo ( P < 0.001) 1 |
Hiddeman et al[5] | 2005 | No | R-CHOP vs CHOP | 428 | 96% vs 90% (P = 0.001) | 95% vs 90% at 2 yrs (P =0.016) | 91% vs 79% at 2 yrs ( P < 0.001)1 |
van Oers et al[6,7] | 2006, 2010 | Yes | R-CHOP vs CHOP | 465 | 85% vs 72% (P < 0.001) | 82% vs 79% at 3 years (P = 0.09) | 33 vs 20 mo ( P < 0.001) |
Forstpointner et al[10] | 2006 | Yes | R-FCM vs FCM | 125 | 95% vs 71% (P = 0.01) | Not available2 | Not available2 |
Herold et al[9] | 2007, 2010 | No | R-MCP vs MCP | 358 | 92% vs 75% (P < 0.001) | 86% vs 74% at 5 years (P = 0.02) | 86 vs 35 mo ( P < 0.001) |
Salles et al[8] | 2000 | No | R-CHVP-I vs CHVP-I | 358 | 94% vs 85% (P < 0.001) | 84% vs 79% at 5-years (P = 0.15) | 53% vs 37% at 5 years (P < 0.01) |
Table 2 Randomized trials comparing rituximab maintenance vs observation after single agent rituximab
Reference | Year | Prior treatment | Maintenance schedule | No. of patients | Median F-up | PFS | OS |
Haisworth et al[16] | 2005 | R x 4 (weekly) | R x 4 (weekly) every 6 mo x 4 vs R x 4 weekly at relapse (retreatment) | 62 | 41 mo | 31.3 vs 7.4 mo (P = 0.007) | 72% vs 68% at 3 years (P = NS) |
Ghielmini et al[14] Martinelli et al[19] | 2004 | R x 4 (weekly) | R every 2 mo x 4 vs observation | 185 | 9.5 years | 24 vs 13 mo (P < 0.001) | 68% vs 54% (P = 0.081) |
2010 |
Table 3 Randomized trials comparing rituximab maintenance vs observation after chemotherapy or immunochemotherapy
Reference | Year | Prior treatment | Maintenance schedule | No. of pts | Median F-up | PFS | OS |
Hochster et al[17] | 2009 | CVP (1st line) | R x 4 (weekly) every 6 mo x 4 vs observation | 228 | 3.7 years | Median: 4.3 vs 1.3 years; At 3 years: 64% vs 33% ( P < 0.001) | At 3 years: 91% vs 86% (P = 0.08) |
Forstpointner et al[10] | 2006 | FCM or R-FCM (relapsed disease) | R x 4 (weekly) every 6 mo x 2 vs observation | 105 | 26 mo | Median: Not reached vs 16 mo (P < 0.001) | At 3 years (estimated): 77% vs 57% (P = 0.1) |
van Oers et al[6,7] | 20062010 | CHOP or R-CHOP (relapsed disease) | R every 3 mo x 8 vs observation | 334 | 6 years | Median: 3.7 vs 1.3 years; At 3 years: 59% vs 28% (P < 0.001) | At 5 years: 74% vs 64% (P = 0.07) |
Salles et al[18,23] | 2010 | R-CHOP, R-CVP, R-FCM (1st line) | R every 2 mo x 12 vs observation | 1018 | 25 mo | At 2 years: 79% vs 60% (P < 0.001) | At 2 years: NS |
Table 4 Toxicities in trials comparing rituximab maintenance vs observation in follicular lymphoma
Reference | No of. patients | Grade 3-4 AE | Neutropenia (grade 3-4) | Grade 3-4 Infections |
Haisworth et al[16] | 62 | 9% vs 4% | 2% vs 0% | 0 |
Ghielmini et al[14] Martinelli et al[19] | 185 | 28% vs 20% | 18% vs 17% | NA |
Hochster et al[17] | 228 | NA | 3% vs 1% | 1% vs 1% |
Forstpointner et al[10] | 105 | NA | 13% vs 6% | 4% vs 3% |
van Oers et al[6] | 334 | NA | 10.8% vs 5.4%(P = 0.07) | 9% vs 2.4% (P = 0.009) |
Salles et al[18,23] | 1018 | 23% vs 16% | 4% vs 1% | 4% vs 1% |
- Citation: Arcaini L, Merli M. Rituximab maintenance in follicular lymphoma patients . World J Clin Oncol 2011; 2(7): 281-288
- URL: https://www.wjgnet.com/2218-4333/full/v2/i7/281.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i7.281